
CONCOMITANT ADMINISTRATION OF LIQUID PORCINE CIRCOVIRUS-FREE HUMAN ROTAVIRUS VACCINE WITH ROUTINE PEDIATRIC VACCINES DOES NOT IMPACT IMMUNE RESPONSES IN INFANTS: RESULTS FROM A PHASE 3, RANDOMIZED TRIAL IN THE UNITED STATES

<u>Remon Abu-Elyazeed</u>, MD, PhD¹, Nicola P. Klein, MD, PhD², Leentje Moerman, PhD³, Michael Povey, MSc³, Anthony Pruitt, MD⁴, Shelly Senders, MD⁵, Peter Silas, MD⁶, and Dan Bi, MD, MPH³ ¹GSK, Philadelphia, Pennsylvania, US; ²Kaiser Permanente Vaccine Study Center, Oakland, California, US; ³GSK, Wavre, Belgium; ⁴Wee Care Pediatrics, Roy, Utah, US; ⁵Senders Pediatrics, Cleveland, Ohio, US; ⁶Wee Care Pediatrics, Syracuse, Utah, US

BACKGROUND AND AIM


- Porcine circovirus type 1 (PCV-1) material was detected in the human rotavirus vaccine (Rotarix, GSK)¹
- Although no safety risk was identified for infants vaccinated with Rotarix, a PCV-free vaccine (no detection of PCV-1 and PCV-2 according to the limit of the tests used) was developed, with comparable immunogenicity and safety profile to the initial Rotarix^{1,2}
- We assessed the immunogenicity and safety of routine vaccines when (co-)administered with PCV-free Rotarix liquid (Liq) or Rotarix lyophilized (Lyo) in infants

METHODS



References: 1. Dubin G, et al. Hum Vaccin Immunother. 2013;9:2398–408; **2.** Salamanca de la Cueva I, et al. J Infect Dis. 2020. Epub ahead of print (doi: 10.1093/infdis/jiaa210).

Funding: GlaxoSmithKline Biologicals SA funded the study, abstract and poster development. **Trademark statement:** Rotarix is a trademark owned by or licensed to the GSK group of companies. **Acknowledgements:** The authors thank the Rota-090 Study group. Medical writing and editorial support were provided by Noemi Bulik and Manuel Zocco (Modis c/o GSK). Immune responses to routine vaccine antigens were not inferior for (co-)administration with PCV-free *Rotarix* Liq vs (co-)administration with *Rotarix* Lyo



A 10% decrease in seroresponse to PT, FHA and PRN antigens when DTaP-HBV-IPV was co-administered with PCV-free *Rotarix* Liq compared to when DTaP-HBV-IPV was co-administered with the currently licensed *Rotarix* Lyo was ruled out*

Per-protocol set. LL, lower limit of the 95% confidence interval; HBs, hepatitis B surface antibody; GMC, geometric mean concentration; PT, pertussis toxoid; FHA, filamentous hemagglutinin; PRN, pertactin; PRP, polyribosyl-ribitol phosphate. *Scan for more details.

Presenting author: Remon Abu-Elyazeed Address: 5 Crescent Drive, Philadelphia, PA 19112 E-mail: remon.abu-elyazeed@gsk.com Telephone: +1215-751-3942 Cell: +1-484-919-3288

KEY MESSAGES




 Routine vaccines (co-)administered with PCV-free Rotarix Liq showed non-inferior immune responses and similar safety profiles compared to (co-)administration with Rotarix Lyo

I


Routine vaccines have similar immunogenicity and safety profiles when administered with either PCV-free Rotarix Liq or Rotarix Lyo in infancy
PCV-free Rotarix Liq could be used as part of routine vaccination in the United States

RESULTS





- Seroprotection/seropositivity rates were ≥99.3% for all DTaP-HBV-IPV antigens, ≥97.4% for Hib and ≥90.8% for most PCV13 serotypes
- Geometric mean concentrations/titers for the routine vaccine antigens were comparable between groups (scan see for more details)
- The percentage of infants with anti-rotavirus antibody concentration ≥20 U/mL was similar between PCV-free Rotarix Liq (76.3%) and Rotarix Lyo (78.9%)



Exposed set. N, number of infants with at least one documented dose; any fever, \geq 38.0°C. Scan for definition of Grade 3 AEs.

Similar incidence of unsolicited AEs and SAEs was observed between groups

75 SAEs: 2 (*Rotarix* Lyo: abdominal distension; intussusception) considered vaccine-related by the investigator, both resolved within 2 days; 1 fatal SAE (PCV-free *Rotarix* Liq: sudden infant death syndrome) considered non-vaccine-related by the investigator



